3 research outputs found
Once-weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8-GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial).
Introduction
Turoctocog alfa pegol (N8âGP) is a siteâspecific, 40 kDa glycoPEGylated recombinant factor VIII (FVIII) product with an extended halfâlife. The comprehensive main phase of the pivotal pathfinder 2 trial showed N8âGP dosed every 4 days (Q4D) provided favourable safety and efficacy for preventing bleeds in 175 patients with haemophilia A.
Aim and methods
We investigated the safety and efficacy of N8âGP prophylaxis when administered weekly (Q7D) for 24 weeks to patients with low bleeding rates in the pathfinder 2 extension trial. Patients (â„12 years) with â€2 bleeds during the preceding 6 months of the pathfinder 2 main phase were eligible for randomization to receive N8âGP 50 IU/kg Q4D or 75 IU/kg Q7D. Safety and efficacy endpoints were incidence of FVIII inhibitors and annualized bleeding rate (ABR), respectively.
Results
Fiftyâfive of 143 (38.5%) patients on prophylaxis who continued into the extension phase were randomized to receive 50 IU/kg Q4D (n = 17) or 75 IU/kg Q7D (n = 38). Nine patients in the Q7D cohort reverted to 50 IU/kg Q4D. No inhibitors were detected. In both cohorts, >50% of patients experienced no bleeds. Median ABR for overall, joint, spontaneous, traumatic and muscle was 0.00 for both cohorts. Overall estimated success rate for treating bleeding episodes was 87.5%; 94.7% of bleeds were controlled with â€2 injections.
Conclusions
Weekly N8âGP was well tolerated and efficacious and may benefit selected âlow bleederâ patients with haemophilia A